Home Clinical trials For patients Uterus BGOG-EN25/BNT323-01

BGOG-EN25/BNT323-01

A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer

Open
Trial drug
BNT323/DB1303
Grade
High grade, Low grade, Other / unknown
Prior lines
1, 2, 3
Histology
Endometrioid, Mucinous Serous Clear-cell Carcinocarcoma Other (bv. mixed/rare)
Phase
III

Treatment

Participants will be randomized 2:1 to receive either BNT323/DB-1303 or investigator's choice of single agent chemotherapy (doxorubicin or paclitaxel).

Treatment duration

The treatment with BNT323/DB1303 can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.